Analytics Startup Genoox Lands $6M Investment, Enters US Market

Jul 11, 2017

|

CHICAGO (GenomeWeb) – Genomic analysis startup Genoox announced today that it has raised $6 million in private equity investment and is entering the US market.

Two Israeli venture firms, Inimiti Capital Partners and Glilot Capital Partners, led the round, with participation from several unspecified "investors from the genetic field," Tel Aviv, Israel-based Genoox said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

From a Clay Pipe to Sierra Leone

Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.

Shawl Analysis

Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.

Japan to Issue Gene-Edited Food Rules

Japan is to release rules governing some gene-edited food, according to NHK World.

This Week in PLOS

In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.

Featured White Papers

Whole Genome Sequencing of Microbial Communities for Scaling Microbiome and Metagenomic Studies

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

Mar

28

Featured Webinar

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.

Apr

09

Featured Webinar

Combining AI with Community-Driven Insights: Advanced Diagnosis of Inherited Cardiac Diseases

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies.

Menu